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Abstract
Background: Seroprevalence data and clinical studies in children suggest that the burden of pneumocystis
pneumonia (PCP) in Africa may be underestimated. We performed a systematic review to determine the
prevalence and attributable mortality of PCP amongst HIV-infected adults in sub-Saharan Africa.
Methods: We searched Pubmed, Web of Science, Africa-Wide: NiPAD and CINAHL, from Jan 1 1995 to June 1 2015,
for studies that reported the prevalence, mortality or case fatality of PCP in HIV-infected adults living in sub-Saharan
African countries. Prevalence data from individual studies were combined by random-effects meta-analysis according
to the Mantel-Haenszel method. Data were stratified by clinical setting, diagnostic method, and study year.
Results: We included 48 unique study populations comprising 6884 individuals from 18 countries in sub-Saharan
Africa. The pooled prevalence of PCP among 6018 patients from all clinical settings was 15 · 4 % (95 % CI 12 · 9–18 · 0),
and was highest amongst inpatients, 22 · 4 % (95 % CI 17 · 2–27 · 7). More cases were identified by bronchoalveolar
lavage, 21 · 0 % (15 · 0–27 · 0), compared with expectorated, 7 · 7 % (4 · 4–11 · 1), or induced sputum, 11 · 7 % (4 · 9–18 · 4).
Polymerase chain reaction (PCR) was used in 14 studies (n = 1686). There was a trend of decreasing PCP prevalence
amongst inpatients over time, from 28 % (21–34) in the 1990s to 9 % (8–10) after 2005. The case fatality rate was
18 · 8 % (11 · 0–26 · 5), and PCP accounted for 6 · 5 % (3 · 7–9 · 3) of study deaths.
Conclusions: PCP is an important opportunistic infection amongst HIV-infected adults in sub-Saharan Africa,
particularly amongst patients admitted to hospital. Although prevalence appears to be decreasing, improved
access to antiretroviral therapy and non-invasive diagnostics, such as PCR, are needed.
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Background
Pneumocystis jirovecii is a ubiquitous opportunistic fungal
pathogen that causes pneumocystis pneumonia (PCP) in
patients with cellular immune defects. PCP heralded the
onset of the global human immunodeficiency virus (HIV)
pandemic [1], and prior to 1995 it was estimated that
two-thirds of HIV-infected persons would eventually
develop PCP [2]. Although the incidence has declined
since the introduction of cotrimoxazole prophylaxis and
combination antiretroviral therapy (ART), PCP remains
the most important AIDS-defining opportunistic infection
in the United States [3, 4]. By contrast, in sub-Saharan Af-
rica the morbidity and mortality in HIV is dominated by
tuberculosis [5], cryptococcal disease, and bacterial infec-
tions such as non-typhoidal salmonella and Streptococcus
pneumoniae [6].
Early studies from African countries with high HIV
prevalence reported PCP to be an uncommon OI [7–9].
An overwhelmingly high burden of other opportunistic
diseases, early exposure to P. jirovecii resulting in
improved immunity, and immune modulation by other
infections are putative explanations for the reduced
prevalence of PCP in sub-Saharan Africa [10–12]. A
single recent study demonstrated an inverse relationship
of PCP prevalence to gross domestic product [13].
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In the context of late presentation at low CD4 T
lymphocyte counts (CD4 count) [14] and limited ART
coverage [15], there is potentially a large pool of individ-
uals at high risk of presenting to health care facilities with
PCP in sub-Saharan Africa. Local studies have revealed a
high seroprevalence of P. jirovecii in healthy HIV-infected
adults [16, 17], as well as high rates of clinical disease in Af-
rican children [18–20]. The reported increase in prevalence
amongst adults in the 1990s, possibly as a result of better
access to diagnostics and treatment [21], may reflect the
true epidemiology of the disease, suggesting that PCP may
be a more important cause of community-acquired pneu-
monia in Africa than was previously recognised.
A better understanding of PCP prevalence will help to
inform empiric prescribing, the interpretation of diagnos-
tic tests, and public health policy relating to the allocation
of scarce resources such as intensive care unit beds, inva-
sive procedures like bronchoscopy, and research funding.
We therefore undertook a systematic review to more ac-
curately determine the burden of PCP in sub-Saharan Af-
rica in the ART era. Our primary aim was to determine
the proportion of HIV-infected adults with confirmed
PCP, stratified by clinical setting, method of diagnosis, and
time. Secondary aims included attributable mortality and
case fatality, a description of demographic profiles, and
rates of co-infection with other pathogens.
Methods
Search strategy and selection criteria
A detailed protocol describing our methods has been
published elsewhere [22] and is registered in the Prospero
database (CRD42013005530). We developed a broad
search strategy to identify studies that reported the preva-
lence, mortality or case fatality of PCP in sub-Saharan
Africa. Our systematic review used the search terms
“pneumocystis,” “P jirovecii,” “P carinii,” “pneumonia,”
“HIV,” “Africa south of the Sahara,” and related terms for
relevant studies published in Pubmed, Web of Science,
Africa-Wide: NiPAD and CINAHL between 1995 and
1 June 2015 (the full search strategy is included in the
supplementary appendix, Additional file 1). No language
or age limits were applied. We hand-searched bibliograph-
ies of all recovered articles for potentially eligible studies
and contacted authors for unpublished data. The year
1995 was chosen as a cut-off because previous reviews
have reported on PCP prevalence from early studies in
sub-Saharan Africa, and we wanted to assess the impact of
more widespread availability of cotrimoxazole prophylaxis
and ART. Titles and abstracts of references recovered
by the search were screened and the full texts of poten-
tially relevant articles were independently assessed by two
reviewers (SW and RG) using a standardised score sheet.
Disagreements on final inclusions were resolved by discus-
sion and consensus involving a third reviewer (MM).
Studies assessing a clearly defined population of HIV-
infected adults (≥13 years of age, chosen because the diag-
nosis and treatment of PCP in this age group is identical
to older adults, and 13 years is the age of transition into
adult care in the public health sector in South Africa) in
any clinical setting were included if they applied specific
diagnostic criteria for PCP. These were predefined with
the use of a novel quality-scoring tool, and included either
a clear clinical case definition (based on World Health
Organization criteria [23]) or confirmation with laboratory
testing (using histochemical or fluorescent staining or
molecular assays). Reports involving cohorts of patients
with PCP were ineligible for primary analysis of pooled
prevalence, but were included if they provided data on
case fatality.
Data extraction
Data were independently extracted by two reviewers (SW
and RG) and compared for consistency using pre-specified
scores derived for each main eligibility category. The key
variable was the proportion of HIV-infected adults in the
study cohort diagnosed with PCP. As a minority of studies
were specifically designed to assess this outcome, our
denominator was defined as the population of patients
who underwent clinical or laboratory evaluation for PCP.
Prevalence was defined as the number of cases of PCP
diagnosed among patients with signs and symptoms of
PCP who would normally warrant testing at a given hos-
pital or clinic, and not the population prevalence of disease.
We defined mortality and case fatality as the proportion of
deaths due to PCP (PCP deaths/total deaths) and mortality
amongst PCP cases (PCP deaths/total PCP diagnoses),
respectively.
Data were stratified by clinical setting. As an indicator of
severity and as a crude estimate of the pre-test probability
of PCP, we categorised in- and outpatients into separate
groups, given that susceptible inpatients with respiratory
symptoms are more likely to have a diagnosis of PCP and
to have more severe disease than outpatients, which will
influence PCP prevalence and mortality. Studies that
recruited both in- and outpatients, but from which the
respective proportions of these groups could not be ascer-
tained, were classified separately. We also stratified data
by diagnostic method and clinical specimen.
Patients with symptoms compatible with PCP plus any
positive diagnostic test or fulfilling criteria for the clinical
case definition were considered to have confirmed disease,
and were included in our primary analysis. Asymptomatic
individuals or those with an illness that resolved without
specific PCP therapy, but had a positive P. jirovecii PCR
(any assay) were defined as being colonised.
Where available, the following information was cap-
tured; CD4 count, numbers of patients on cotrimoxazole
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prophylaxis and/or ART, type and frequency of co-infec-
tion(s), relevant data from studies with duplicate co-
horts that were excluded from the pooled prevalence
analysis, and demographic details.
Methodological quality of included studies
Overall quality of included studies was evaluated using our
published scoring system [22]. The tool assigns numerical
scores to the following domains: participant selection
(study design and objectives), outcome ascertainment
(diagnostic criteria) and quality of data available for extrac-
tion. We used the tool to code and standardise study
eligibility decisions and to assess agreement between inves-
tigators. As this is a prevalence review, we assessed studies
for selection bias and overall bias, using criteria defined by
the Cochrane group (Review Manager Version 5.2, http://
ims.cochrane.org/RevMan).
Data analysis
Point estimates and 95 % confidence intervals were derived
for all outcomes using prevalence data from included
studies. Meta-analysis was performed according to the
Mantel-Haenszel method applying the random-effects
model to account for between study variability. We evalu-
ated heterogeneity using the χ2-based Q statistic (signifi-
cant for p <0 · 1) and the I2 statistic (>50 % indicative of
“notable” heterogeneity) [24]. STATA software version 11
(STATA Corporation, College Station, Texas) was used to
perform calculations and the meta-analysis and to produce
the forest plots using the metan routine. Where standard
errors (SE) were not provided, we incorporated confidence




Our search identified 1862 records, with an additional five
studies added from searching bibliographies. After remo-
ving duplicates and screening abstracts for relevance to
the study aims, we evaluated 185 full text articles for eligi-
bility, ultimately including 48 unique study populations
(Fig. 1; a full reference list of included studies available in
Fig. 1 PRISMA flow diagram
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the online supplementary appendix, Additional file 2). Of
these, 35 studies (6018 patients) reported the prevalence
of PCP from clinical cohorts; eleven were post-mortem
studies (707 deaths) and two provided data on clinical
characteristics and case fatality only. For the studies with
a clear denominator to evaluate PCP prevalence, the
pre-defined clinical categories were represented as follows:
inpatients, 23 studies (n = 2593); outpatients, 7 studies
(n = 2656); and enrolment of both in- and outpatients, 5
studies (n = 769). The dataset included patients from
18 sub-Saharan African countries: Benin, Burkina Faso,
Central African Republic, Mali, Mozambiqe, Nigeria,
Namibia and Zambia (1 study); Botswana and Zimbabwe
(2 studies); Côte d’ Iviore, Ethiopia, Malawi, Senegal and
Tanzania (3 studies); Kenya (4 studies); Uganda (8 studies);
South Africa (13 studies). Apart from 3 clinical studies
that recruited patients from district hospitals, all others
were conducted in tertiary or central hospital referral
centres.
Study characteristics are summarised in the online
supplementary appendix (Additional file 3). The median
CD4 count of patients assessed for PCP was 75 cells/
mm3 (interquartile range (IQR) 63–145; 20 studies, n =
3543). 18 · 7 % (983/5249) were on ART (26 studies, n =
5249) and 34 · 4 % (1377/4002) were receiving PCP
prophylaxis (21 studies, n = 4002).
Although most studies (42, n = 6285) were prospective
in design the overall data quality was poor: risk of bias
was assessed as high in 30 studies (n = 4346) and 19 stud-
ies (n = 4140) were assigned an overall quality assessment
score of ≤ 9 (poor quality) (available in the online supple-
mentary appendix, Additional file 4). Agreement between
investigators with regard to decisions about applied quali-
tative scores was acceptable (interrater agreement =
95 · 12 %, kappa = 0 · 8292).
PCP prevalence
The overall prevalence of PCP among 6018 patients in 35
clinical studies was 15 · 4 % (95 % confidence interval (CI),
12 · 9–18 · 0) (Fig. 2). Heterogeneity was high (p < 0 · 1;
I2 = 95 · 6 %). Among all patients presenting with re-
spiratory symptoms the prevalence was 18 · 8 % (31
studies, n = 3504, 95 % CI, 14 · 9–22 · 6), and 17 · 1 %
(21 studies, n = 2086, 95 % CI 12 · 5–21 · 7) in studies that
evaluated patients who were sputum smear-negative for
acid-fast bacilli.
The proportions of PCP cases stratified by clinical
setting, post mortem reports, time period studied and
diagnostic methods used, are shown in Fig. 3. By setting,
prevalence was highest amongst inpatients (22 · 4 %, 23
studies, n = 2593, 95 % CI 17 · 2–27 · 7) compared with
outpatients (4 · 8 %, 7 studies, n = 2656, 95 % CI 2 · 7–6 · 9)
and patients recruited from both in- and outpatient
settings (11 · 5 %, n = 769, 95 % CI 4 · 1–19 · 0). PCP was
diagnosed in 24 % (22 studies, n = 1769, 95 % CI 17 · 8–
30 · 3) of inpatients with respiratory symptoms.
Figure 3a shows the comparison of PCP prevalence for
inpatients by the year that data was last collected in the
study. The pooled percentages of PCP cases amongst
inpatients over three time periods were as follows: 1990s,
28 % (4 studies, n = 192, 95 % CI 21–34), 2000–2004, 27 %
(8 studies, n = 633, 95 % CI 23–30), 2005 and later, 9 %
(11 studies, n = 1768, 95 % CI 8–10).
The proportion of inpatients on either ART or cotri-
moxazole in the two earlier time periods was 3 · 6 %
(n = 276, 95 % CI 1 · 8–6 · 6) and 2 · 6 % (n = 227, 95 % CI
0 · 98–5 · 7) respectively, and the proportions in the years
after 2005 were 24 · 3 % (n = 1482, 95 % CI 9 · 8–38 · 7)
and 30 · 4 % (n = 1421, 95 % CI 11 · 6–49 · 3) respectively.
PCP prevalence according to diagnostic method is shown
in Fig. 3b. The prevalence for clinical specimens diagnosed
by BAL was 21 · 0 % (n = 1591, 95 % CI 15 · 0–27 · 0); this
was significantly higher than from expectorated sputum
(7 · 7 %, n = 740, 95 % CI 4 · 4–11 · 1), and numerically
higher than from induced sputum (11 · 7 %, n =553, 95 %
CI 4 · 9–18 · 4). The type of clinical specimen was not speci-
fied in 3 studies (n = 445, PCP cases 40).
Case fatality, mortality and clinical characteristics
The clinical characteristics of PCP cases, proportions
and type of co-infections are listed in table 1. The case
fatality was 18 · 8 % (95 % CI 11 · 0–26 · 5; range 0–71 ·
4 %); data for this calculation were available from 12 stud-
ies (n = 334), representing fewer than half (334/716) of all
confirmed cases. Only two studies (n = 16) reported follow
up times; 11 patients were followed for 1 month (0
deaths) and five followed for 2 months post-discharge
(case fatality 60 %). All other PCP-related deaths oc-
curred during the index admission. 29 · 5 % of the 474 PCP
cases in whom additional testing was performed had a
confirmed co-existent opportunistic pulmonary disease.
Tuberculosis was most common (14 · 8 %), followed by
bacterial pneumonia (8 · 7 %) and Kaposi sarcoma (4 · 1 %).
Where data were available, PCP accounted for 6 · 5 %
(95 % CI 3 · 7–9 · 3) of the overall mortality (17 studies,
n = 1110). Post-mortem studies provided data for 707
deaths of which 5 · 9 % (95 % CI 3 · 2–8 · 6) were attri-
buted to PCP. Apart from one study that evaluated
all-cause maternal mortality, the primary objectives of
other post-mortem studies included the determination of
cause of death in HIV-infected adults. Three of these stud-
ies (n = 221) enrolled subjects with pre-morbid respiratory
symptoms, in whom PCP-related mortality was 10 %
(95 % CI 6–14).
Discussion
Early studies conducted in sub-Saharan Africa suggested
a lower PCP prevalence than in developed countries
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[25–27], as well as a lower incidence (5 cases per 1000
person years) compared to the post-ART era estimate in
the United States of 46 cases per 1000 person years [28].
These data have led a number of experts to question the
importance of PCP in comparison to tuberculosis and
other infections that dominate mortality and morbid-
ity in sub-Saharan Africa [10–12]. Our review of data
collected predominantly after 1995 demonstrates a
pooled prevalence of PCP comparable to that re-
ported from developed countries [29], suggesting that
it is more likely to have been missed or neglected in
sub-Saharan Africa rather than being an uncommon
opportunistic infection.
Previous reviews have shown time trend of increasing
PCP prevalence in sub-Saharan Africa amongst compa-
rable patient populations and diagnostic assessments.
After crudely combining the data from these reports,
seven out of ten studies conducted over the period
1986–1993 had prevalence rates ≤ 15 % while eight out
of ten studies conducted between 1997 and 2005 had
prevalence rates ≥ 30 % [21, 30]. We have shown the op-
posite, that the proportion of inpatients with PCP appears
to be decreasing over time. This trend seems more realistic,
and it is plausible that our observation of better exposure
to ART and cotrimoxazole prophylaxis in more recent
years can account for fewer diagnosed cases of PCP.
Nonetheless, even after 2005, most patients in our in-
cluded studies had not received these interventions and
had low CD4 counts at presentation, reflecting the slow
rollout of adequate HIV care in the region.
We noted a much higher prevalence of PCP amongst
inpatients compared to outpatients. This is mainly a
reflection of the superior performance of invasive
diagnostic tests and that inpatients represent a selected
denominator of patients that have failed empiric ther-
apy for other causes of pneumonia in the community.
However, the observation may also suggest something
inherent about PCP itself, possibly that mild cases
either resolve spontaneously or are an uncommon
manifestation of the infection; these hypotheses require
further study.
More cases of PCP were diagnosed using BAL (21 %)
compared with sputum (7–11 %). This reflects a selec-
tion bias of patients with a higher likelihood of PCP be-
ing referred for bronchoscopy but also the enhanced
sensitivity of BAL for diagnosis. Unfortunately, access to
bronchoscopy is extremely limited in most African
countries, and clinicians must rely on a combination of
knowledge of disease prevalence, unvalidated clinical
case definitions and insensitive non-invasive tests to
Effect Size (95% CI)
Fig. 2 Pooled prevalence of PCP across all clinical settings
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diagnose PCP. In the context of a prevalence of > 20 %
and poor diagnostic tools, there should be a low thresh-
old to initiate empiric PCP therapy for HIV-infected
inpatients with pneumonia. This may lead to overtreat-
ment, with the attendant risks of unnecessary exposure
to high dose cotrimoxazole and concerns about using
corticosteroids in patients with undiagnosed tubercu-
losis or Kaposi sarcoma. Our finding of a high frequency
of PCP with the use of bronchoscopy therefore empha-
sises the need for more accurate non-invasive diagnostic
tests such as PCR, which has been shown to be sensitive,
specific and cost effective when used on sputum and BAL
[31], with a potentially important role as a rule-out test
for PCP in resource-limited settings [32]. Only ten studies
included in our review used PCR assays to diagnose PCP,
and similar numbers of cases were identified by this
method and staining techniques on all specimen types.
Our study was not designed to assess the performance of
diagnostic tests for PCP, and prospective cohort studies
are needed to evaluate the role of PCR, and other non-
invasive tests such as plasma beta-glucan [33], in the diag-
nosis of PCP in sub-Saharan Africa.
Our calculated case fatality of almost 19 % is higher than
the mortality from other common respiratory infections
in Africa [34, 35] as well as from PCP in developed coun-
tries [36]. This contributes to the overall burden of PCP
and adds impetus to more investment in prevention strat-
egies and effective diagnostic tests.
Fig. 3 Forest plots of proportion of patients with PCP by clinical setting, mortality and time period (a) and by diagnostic method (b). PM post
mortem, resp respiratory BAL bronchoalveolar lavage, PCR polymerase chain reaction, Exp expectorated, Ind induced. Heterogeneity: A: Clinical Setting, p<
0.1; I2 = 99.4 %; Mortality, p= 0.83; I2 = 0.0 %; Time Period, p< 0.1; I2 = 91.8 %. B: BAL, p= 0.62; I2 = 0.0 %; expectorated sputum, p= 0.51; I2 = 0.0 %;
induced sputum, p< 0.1; I2 = 71.9 %
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Similarly to a recent review [13], a substantial num-
ber of patients with PCP were found to have coexist-
ent bacterial pneumonia and other opportunistic
infections, particularly tuberculosis. This is an import-
ant consideration when evaluating patients with inad-
equate responses to empiric or confirmed PCP
therapy, and co-infections should be excluded before
attributing a poor treatment response to PCP infec-
tion alone.
This review has a number of important limitations.
First, most included studies were conducted in
highly selected cohorts, such as patients with sus-
pected PCP, exclusion of patients with tuberculosis
and other illnesses, and the performance of BAL
only in cases where the diagnosis remained elusive.
This increases the risk of selection bias and of over-
estimating true disease prevalence. However, the
clinical burden of PCP in a population is influenced
almost exclusively by those who are ill with
respiratory symptoms and our chosen denominator
therefore allows an assessment that is probably close
to the true prevalence.
Second, missing or unreported data was common.
With regard to disease prevalence, bronchoscopy
studies frequently excluded a substantial proportion
of patients with possible PCP on the basis of med-
ical contraindications for the procedure, and five
studies excluded patients with either advanced HIV
or severe respiratory illness. If anything, this may result
in an underestimate of PCP prevalence because the out-
comes of otherwise eligible patients with respiratory
symptoms not enrolled were rarely reported and over half
of the included studies did not specifically evaluate partici-
pants for PCP.
The third limitation was the high degree of hetero-
geneity in the prevalence findings from different stud-
ies. This is not unusual in prevalence reviews, and
reflects differences in methodology and aims, diagnos-
tic methods and the chosen population denominator.
We attempted to minimise this effect by analysing
data by clinical setting to include patients with similar
risk for PCP and by scoring the quality of each study,
and found no significant difference in prevalence on
the basis of study quality (data not shown). It is also
possible that some undefined environmental or biological
differences exist across geographic locations to explain the
observed heterogeneity, but our study was not designed to
address this.
Conclusions
We have performed a systematic review of PCP preva-
lence using diagnostic criteria with high specificity, a
well-defined population denominator and clinically rele-
vant categorisation of cases. The overall impression from
our pooled data is that PCP is an important cause of
community-acquired pneumonia in HIV-infected adults
living in sub-Saharan Africa. This has implications for
clinical guidelines in resource poor settings where indi-
cations for empiric therapy and referral need to be
clearly defined. The contribution of PCP to mortality in
the region suggests that cases are unrecognised, and
highlights the need for the development of a reliable
clinical case definition and the evaluation of sensitive
non-invasive diagnostic tests, such as PCR. The ob-
served trend of decreasing PCP prevalence is encour-
aging, but there is much work to be done to expand
access to ART and cotrimoxazole prophylaxis so that ul-
timately this sentinel AIDS-defining infection achieves
the status of a rare disease it was once erroneously
ascribed.
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Table 1 Characteristics of all PCP cases (n = 743)
Age (years, mean) 35 (10 studies, n = 240)
Male sex (%) 39.6 (15 studies, n = 315)
CD4 count (cells/microL,
median, IQR)
48 [31.5–129.0] (16 studies, n = 353)
Cotrimoxazole prophylaxis
(%, 95 % CI)
5.9 [3.3–9.5] (11 studies, n = 255)
ART (%, 95 % CI) 0.4 [0.01–2.6] (11 studies, n = 215)
Co-existent opportunistic disease (%, 95 % CI)
- Overall 29.3 [25.4–33.6] (26 studies, n = 474)
- Tuberculosis 14.8 [11.8–18.5] (25 studies, n = 431)
- Bacterial pneumonia 8.7 [0.6–11.8] (22 studies, n = 445)
- Pulmonary cryptococcosis 1.4 [0.4–3.6] (17 studies, n = 283)
- Pulmonary Kaposi sarcoma 4.1 [2.4–6.6] (21 studies, n = 410)
- Pulmonary CMV 3.9 [1.4–8.2] (11 studies, n = 155)
- Pulmonary MAC 0.8 [0.1–2.8] (19 studies, n = 254)
Case fatality rate (%, 95 % CI) 18.8 % [11.0–26.5] (12 studies, n = 334)
IQR interquartile range; CI confidence interval; ART antiretroviral therapy;
CMV cytomegalovirus; MAC mycobacterium avium complex
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